Astellas Pharma, Inc.
http://www.astellas.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Astellas Pharma, Inc.
Veozah Warning On Liver Injury Could Present New Commercial Roadblock
The US FDA updated labeling for Astellas’ drug for hot flashes after a postmarketing report of a single patient with signs and symptoms of liver injury taking the medicine.
Lupin Launches Higher Mirabegron Dose ‘At-Risk’
Lupin and Zydus have established a two-player market for their generic versions of mirabegron, while patent litigation with originator Astellas continues on.
What To Look Out For At ESMO 2024
Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.
Multiple Chinese Firms Expand Global Phase III Trials To Japan
The efforts add up to a new trend after Chinese pharma firms embarked on a quest to launch pivotal Phase II or III trials worldwide, especially in the US and Europe, over the past decade. Meanwhile, BeiGene, Hengrui and others are advancing late-stage programs in the US.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Advanced Cell Technology, Inc.
- Agensys, Inc.
- Audentes Therapeutics, Inc.
- Fujisawa GmbH
- Ganymed Pharmaceuticals AG GmbH
- iota Biosciences
- Mytogen, Inc.
- Nanna Therapeutics Limited
- Perseid Therapeutics LLC
- Potenza Therapeutics Inc.
- Ocata Therapeutics, Inc.
- OSI Pharmaceuticals, LLC (Cell Pathways
- Prosidion)
- Yamanouchi Pharmaceutical Co., Ltd.
- Ogeda S.A.
- Mitobridge, Inc.
- Mitokyne, Inc.
- Quethera Limited
- Universal Cells, Inc.
- Xyphos Biosciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice